8.00 am Coffee & Networking

8:45 am Chair’s Opening Remarks

Revolutionizing Clinical Pipeline to Overcome Challenges in Drug Development

9:00 am Enhancing Translatability Ahead of Clinical Trials for Effective Treatment of Prosthetic Joint Infections


  • Developing effective R&D models for phage therapy to improve clinical translatability 
  • Migrating from animal models to human trails – how can this be achieved successfully? 
  • Revamping study design to boost clinical results of phage therapy for prosthetic joint infections 

9:30 am Disrupting Modern Day Medicine: Re-Inventing Strategies Around Phage Drug Development


  • Developing viable medicines that work backwards – starting with the end in mind? 
  • Establishing dynamic endpoints and outcomes of phage therapy that are non-traditional and non-binary 
  • Creating therapeutic phage-based drugs that can outpace infection and disarm bacteria 

Accelerating Our Transition from Agriculture & Animal Health to Human Trials

10:00 am Examining Phage Development Process in the Agricultural Industry: How Can We Translate This Over to Pharmaceuticals?


  • Enabling tailor-made development process of phage-based products for animal health
  • Executing mass production of bacteriophage for industrial animals – at what cost?
  • Unveiling relevant findings from animal health for application in human health

10.30 am Morning Refreshments & Networking

11:30 am Traveling Broadens the Mind: Exploring the Journey from Agritech to Human Health


  • Analyzing how the development of phage products compare across different fields of R&D
  • Diving into what can be learned when shifting perspective from one area of development to another
  • Focusing on IP, manufacturing, and regulation for phage therapy to leverage insights for pharmaceutical advancement

12:00 pm Breaking the Ice: Pioneering Bacteriophage Product Acceptance in the European Regulatory Landscape


  • Examining a case study on the registration of bacteriophage feed additive with the European Commission
  • Identifying gaps in quality standards and regulatory guidance for bacteriophage products
  • Widening public affair initiatives to foster acceptance of bacteriophage technology

12:30 pm Lunch & Networking

1:30 pm Panel Discussion: What Can be Taken from the Agricultural Bacteriophage Industry & Applied to Human Use?


Important strides in phage therapy have been overshadowed by the widespread use of antibiotics to treat diseases in humans and animals. With imprudent application of antimicrobials in agriculture, the industry can no longer dismiss the consequential emergence of antibiotic-resistant human pathogens, increased human mortality, and soaring healthcare costs. Hear out our panelists engage in this 45-minute discussion that will focus on: 

  • Evaluating selection of phage cocktail for effective control of feed disease and targeting of pathogens 
  • Tackling issues with gut microbiome health in animals to better understand the nature of commensal bacteria in humans 
  • Finalizing methods of production and administration with phage therapy in animals that lead to success for translatability in the pharmaceutical industry 

Expanding Applications of Bacteriophage Beyond Antimicrobial Resistance

2:15 pm Characterizing the Role of Microbiome on Human Health to Understand How Bacteriophage Contributes to Preventative Medicine


  • Highlighting the importance of bacteriophage and its interactions with the microbiome in human health and disease
  • Discovering potential endogenous targets and biological processes for phage therapy in humans
  • Applying sequencing at Pfizer to preventative medicine and phage therapy development

2:45 pm Next Therapy for Precision Oncology: Utilizing Bacteriophage for Targeting Microbiome & Applying Synthetic Biology


  • Pioneering bacteriophage therapy to improve the microbiome of compromised cancer patients
  • Understanding the advantages of using bacteriophage therapy in cancer patients in comparison to alternative drug delivery models
  • Exploring the potential use of bacteriophage to modify specific traits in microbiome bacteria

3:15 pm Roundtable Discussion: Evaluating the Future of Natural, Engineered, Hybrid & Synthetic Phage


We will utilize this roundtable session to discover actions and propose solutions for different phage strategies to reach a conclusion on the best patient outcomes. Join this 45-minute discussion to share your challenges and potential approaches to address:

  • Comparative differences between the nature of phage types with respect to clinical trials, followed by the methods of assessing these differences
  • Controversy on whether engineered phage pose less threat to the development of antimicrobial resistance, followed by subsequent concerns for natural phage

4:00 pm Chair’s Closing Remarks & End of Conference Day Two